Liver News and Research

RSS

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..

31 Mar 2011

Micro-RNAs appear to play a key role in new mechanism underlying obesity

Max Planck researchers have discovered a new mechanism that leads to the development of type 2 diabetes in obesity. Body weight influences the risk of developing diabetes: between 80 and 90 percent of patients with type 2 diabetes are overweight or obese.

31 Mar 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Master regulators of cholesterol and fat play key role in liver fibrosis development

UCLA researchers have demonstrated that a key regulator of cholesterol and fat metabolism in the liver also plays an important role in the development of liver fibrosis - the build-up of collagen scar tissue that can develop into cirrhosis. Cirrhosis, in turn, is a major cause of premature death and is incurable without a liver transplant.

31 Mar 2011

Boceprevir drug can help cure hard-to-treat hepatitis C

The drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R. Bacon, M.D., author of the March 31 New England Journal of Medicine article detailing the study's findings.

31 Mar 2011

Three-drug cocktail more effective against hepatitis C virus

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

31 Mar 2011

Could HIV-infected organs save 'lives?

Johns Hopkins researchers argue for reversing ban on transplanting infected organs and making them available to HIV-infected patients

30 Mar 2011

Effervescent formulation of omega-3 fish oil is more rapidly absorbed than gelatin soft gels: Study

A research study conducted earlier this year on two Nordic Naturals® Arctic Cod Liver Oil™ products concluded that the effervescent formulation is more rapidly absorbed than gelatin soft gels, and suggested that the effervescent form is equally palatable, making it an acceptable alternative to the popular soft gel form.

30 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A inhibitor for the treatment of patients with chronic hepatitis C.

30 Mar 2011

Study examines plant-soil relationship and uptake of contaminants in ryegrass

The environmental concern is great when considering the role of toxic contaminants in the plant-soil relationship. Understanding plant's absorption and accumulation of these contaminants from the soil would be incredibly beneficial.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.

30 Mar 2011

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Interventional radiologists have been the leaders in the use of intra-arterial yttrium-90 radioembolization, since its introduction in 2000, to treat liver cancer.

29 Mar 2011

Smoking cessation after liver transplantation reduces incidence of malignancy

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies (SRM) than patients who keep smoking. In fact, SRMs were identified in 13.5% of deceased patients and smoking was associated with a higher risk of malignancy in this study. Full findings are published in the April issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2011

Nycomed submits teduglutide MAA to EMA for SBS treatment

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported that Nycomed, a global pharmaceutical company, headquartered in Switzerland, has submitted a Marketing Authorization Application to the European Medicines Agency for clearance to market teduglutide as a once-daily subcutaneous treatment for short bowel syndrome.

29 Mar 2011

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

Nordion Inc., a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer.

29 Mar 2011

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.

29 Mar 2011

Liver News and Research

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Micro-RNAs appear to play a key role in new mechanism underlying obesity

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Master regulators of cholesterol and fat play key role in liver fibrosis development

Boceprevir drug can help cure hard-to-treat hepatitis C

Three-drug cocktail more effective against hepatitis C virus

Could HIV-infected organs save 'lives?

Effervescent formulation of omega-3 fish oil is more rapidly absorbed than gelatin soft gels: Study

DSP, Intercept enter license agreement for OCA

Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV

Study examines plant-soil relationship and uptake of contaminants in ryegrass

Smoking withdrawal after liver transplantation may protect against neoplasia development

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Smoking cessation after liver transplantation reduces incidence of malignancy

Nycomed submits teduglutide MAA to EMA for SBS treatment

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News